MedTrace Logo

Post Marketing Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp

NCT02646800 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 105

Last updated 2024-11-07

No results posted yet for this study

Summary

The objective of this study is to evaluate the safety and efficacy of intravenous micafungin for the treatment of adult patients in China infected by Candida spp or Aspergillus spp.

Conditions

  • Aspergillosis
  • Candidiasis

Interventions

DRUG

Micafungin

Injection

Sponsors & Collaborators

  • Astellas Pharma China, Inc.

    lead INDUSTRY

Principal Investigators

  • Medical Director · Astellas Pharma Inc

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-21
Primary Completion
2014-12-21
Completion
2014-12-21

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02646800 on ClinicalTrials.gov